Dr. Jonathan C. Trent II, MD, PhD

Dr. Trent practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Trent's NPI, 1780770552, was assigned on October 5, 2006. Dr. Trent graduated from McGovern Medical School in 1995. Dr. Trent holds Florida license ME111336.

Dr. Trent's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Trent's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Dr. Trent is also affiliated with UF Health Shands Hospital. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Trent practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Trent's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Trent is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Trent's licenses on file in 2 states: Florida and Texas.

Dmand AI lists breast cancer, colorectal cancer, lymphoma and prostate cancer among the conditions Dr. Trent treats.

CMS data shows 302 Medicare services from Dr. Trent across 2 procedure codes in 2024, all of them office visits, for 134 Medicare patients. Medicare paid $35,824 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 134 Medicare patients who saw Dr. Trent in 2024. The largest group is 65 to 74, with 52 patients. 72% of them have high cholesterol, and 66% have high blood pressure. 18% are also on Medicaid. Their average risk score is 1.90, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Trent's median patient age at 67, with 57% women.

In 2024, Dr. Trent wrote 56 Medicare Part D claims for 22 patients. 96% of them were for generic drugs. CMS names the drug for 25 of them, across 2 drugs with 11 or more claims each, at $13,367 in total drug cost. In 2023, CMS named 29 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Trent for performance year 2024, reported as part of a group. Dr. Trent accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Trent as offering telehealth.

Dmand AI links 195 papers to Dr. Trent, published from 2006 to 2025. 2021 was the busiest year, with 12. The most frequent topics are Gastrointestinal Stromal Tumors, Imatinib Mesylate and Pyrimidines. Dr. Trent has published most often in Cancer. Dr. Trent's most frequent co-authors are Robert S. Benjamin, MD, Alexander J.f. Lazar, MD, PhD and Breelyn Ann Wilky, MD.

Dmand AI links Dr. Trent to 9 clinical trials, 5 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Gastrointestinal Stromal Tumors, Neoplasms, Connective Tissue and Sarcoma. Eli Lilly and Company sponsors the most, 3. Open Payments lists research payments to Dr. Trent that name 3 trials.

CMS Open Payments shows 361 general payments to Dr. Trent from 30 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 52% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $56,925. It also lists 12 research payments totaling $197,673 from 2016 to 2023, naming 3 clinical trials.

Dmand AI lists 1 award for Dr. Trent, most recently CMS Stage 1 EHR in 2013.

Dr. Trent graduated from McGovern Medical School in 1995. Dr. Trent is a member of ASCO.

Dr. Trent is in network with 12 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.